Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

NCT05210413 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT05210413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05210413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 17, 2022
Completion date
November 17, 2027
Enrollment
80 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

refractory or recurrent solid tumor